Acasti Pharma Inc (ACST):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acasti Pharma Inc (ACST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8191
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acasti Pharma Inc (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, development, and commercialization of krill oil-based forms of omega-3 fatty acids. The company develops phospholipid therapies for abnormalities in blood lipids, and treatment and prevention of various cardiometabolic disorders. Its product include CaPre, a drug product candidate, used for the treatment of hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream; and Onemia, a medical food that is used in the dietary management of diseases associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. The company has operations in Canada. Acasti is headquartered in Laval, Quebec, Canada.

Acasti Pharma Inc (ACST) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acasti Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Acasti Pharma to Enter into Agreement with China-Based Pharmaceutical Company 10
Xymogen Enters Into Distribution Agreement With Acasti Pharm For LipiChol540 11
Equity Offering 12
Acasti Pharma Raises USD19.1 Million in Public Offering of Shares 12
Acasti Pharma Prices Marketed Public Offering of Shares for USD18.7 Million 14
Acasti Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD9 Million 16
Acasti Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD0.7 Million 18
Acasti Pharma Raises USD4.35 Public Offering of Units 20
Acasti Pharma Raises USD4.3 Million in Public Offering of Units 22
Acasti Pharma Completes Private Placement Of Units For US$2 Million 24
Acasti Pharma Completes Public Offering Of Units For US$23 Million 25
Acasti Pharma Completes Private Placement Of Units For US$1 Million 27
Acasti Pharma Completes Private Placement Of Shares For US$1 Million 28
Debt Offering 29
Acasti Pharma Raises USD1.5 Million in Private Placement of 8% Debentures and Warrants Due 2020 29
Acasti Pharma Inc – Key Competitors 31
Acasti Pharma Inc – Key Employees 32
Acasti Pharma Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
Aug 14, 2018: Acasti Pharma provides business update for the first quarter of fiscal 2019 34
Jun 27, 2018: Acasti Pharma Announces Fourth Quarter And Fiscal 2018 Financial Results 36
Feb 13, 2018: Acasti Pharma Reports Third Quarter FY 2018 Financial Results 38
Aug 14, 2017: Acasti Pharma Reports First Quarter FY 2018 Financial Results 40
Jun 06, 2017: Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results 41
Jan 12, 2017: Acasti Pharma Reports Third Quarter 2017 Financial Results 43
Corporate Communications 44
Sep 24, 2018: Acasti Pharma names Jean-François Boily as Vice President of Finance 44
Nov 16, 2017: Acasti Pharma Announces the Election of Its Directors 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acasti Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acasti Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acasti Pharma to Enter into Agreement with China-Based Pharmaceutical Company 10
Xymogen Enters Into Distribution Agreement With Acasti Pharm For LipiChol540 11
Acasti Pharma Raises USD19.1 Million in Public Offering of Shares 12
Acasti Pharma Prices Marketed Public Offering of Shares for USD18.7 Million 14
Acasti Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD9 Million 16
Acasti Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD0.7 Million 18
Acasti Pharma Raises USD4.35 Public Offering of Units 20
Acasti Pharma Raises USD4.3 Million in Public Offering of Units 22
Acasti Pharma Completes Private Placement Of Units For US$2 Million 24
Acasti Pharma Completes Public Offering Of Units For US$23 Million 25
Acasti Pharma Completes Private Placement Of Units For US$1 Million 27
Acasti Pharma Completes Private Placement Of Shares For US$1 Million 28
Acasti Pharma Raises USD1.5 Million in Private Placement of 8% Debentures and Warrants Due 2020 29
Acasti Pharma Inc, Key Competitors 31
Acasti Pharma Inc, Key Employees 32

List of Figures
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Acasti Pharma Inc (ACST):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SMART Technologies Inc.:企業の戦略的SWOT分析
    SMART Technologies Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Wesfarmers Limited:企業の戦略・SWOT・財務分析
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kadant Inc. (KAI):企業の財務・戦略的SWOT分析
    Kadant Inc. (KAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Morgan Advanced Materials plc (MGAM):企業の財務・戦略的SWOT分析
    Summary Morgan Advanced Materials Plc (Morgan) is a diversified company. The company designs, manufactures and markets technical ceramics, thermal ceramics, molten metal systems, electrical carbon, braze alloys, fire protection products, seals and bearings, specialty graphite, and composites and def …
  • LG Corp (003550):企業の財務・戦略的SWOT分析
    LG Corp (003550) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • NanoBio Corp-製薬・医療分野:企業M&A・提携分析
    Summary NanoBio Corp (NanoBio) is a biopharmaceutical company that develops vaccines. The company develops and commercializes intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company's vaccines include anthrax, H5 influenza, pertussis, RSV, HIV, HSV- …
  • British Business Bank Plc:企業の戦略的SWOT分析
    British Business Bank Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Northfork Electric Cooperative Inc:企業の戦略的SWOT分析
    Northfork Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • First Ship Lease Trust (D8DU):企業の財務・戦略的SWOT分析
    First Ship Lease Trust (D8DU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • L&T Finance Holdings Ltd:企業の戦略・SWOT・財務情報
    L&T Finance Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary L&T Finance Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zynerba Pharmaceuticals Inc (ZYNE):企業の財務・戦略的SWOT分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-euphoric cannabinoid, formulate …
  • LM Wind Power Holding AS:企業の戦略的SWOT分析
    LM Wind Power Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • GRP Limited (GRPLTD):企業の財務・戦略的SWOT分析
    GRP Limited (GRPLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Brown Brothers Harriman & Co:企業の戦略的SWOT分析
    Brown Brothers Harriman & Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Tenaris SA:戦略・SWOT・企業財務分析
    Tenaris SA - Strategy, SWOT and Corporate Finance Report Summary Tenaris SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Polymedco Inc-医療機器分野:企業M&A・提携分析
    Summary Polymedco Inc (Polymedco) is a medical device company that manufactures and markets laboratory instruments, reagents and kits. The company provides FIT testing, ESR testing, chemistry testing instruments, oc-auto fit, oc-lights fit, oc-auto sensor, diana, oc-automicro 80, epi procolon, sedit …
  • Cardiovascular Systems Inc (CSII):製品パイプライン分析
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for treating peripheral and coronary vascular disease. The company offers products such as peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accessorie …
  • Comet Ridge Ltd (COI):石油・ガス:M&Aディール及び事業提携情報
    Summary Comet Ridge Ltd (CRL) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company holds interests in Mahalo project located in the Denison trough area of Queensland's Bowen Basin near Rolleston. It also holds interest in PEL 6 …
  • OGE Energy Corp:企業の戦略・SWOT・財務情報
    OGE Energy Corp - Strategy, SWOT and Corporate Finance Report Summary OGE Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Advanced Info Service PLC (ADVANC):企業の財務・戦略的SWOT分析
    Advanced Info Service PLC (ADVANC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆